Abstract
To investigate the molecular identities of L-type calcium channel alpha1C subunit (Cav1.2) and alpha1D subunit (Cav1.3) responsible for motor dysfunction of diarrhea-predominant irritable bowel syndrome (D-IBS). A total of 30 male Wistar rats were randomly divided into two groups. The traditional method for irritable bowel syndrome in a cold environment and intragastric administration of Folium Cassiae were combined to develop the D-IBS model. The fecal particles of rats and the water content in feces were measured. Then the expression of Cav1.2 and Cav1.3 mRNA was detected by reverse transcription polymerase chain reaction. The expressions of Cav1.2 and Cav1.3 were examined by immunohistochemistry in colonic tissues from D-IBS model rats and matched tissues. The fecal particles and the water content in feces of D-IBS model rats significantly increased as compared with the normal rats (6.8 +/- 1.4 vs 3.2 +/- 0.8, P = 0.032, 80% +/- 4% vs 47% +/- 5%, P = 0.018). Cav1.2 and Cav1.3 were positively expressed in colon of both model group and control group rats. The immunohistochemical scores of Cav1.2 and Cav1.3 expression increased in colon of D-IBS model rats as compared with those in normal control rats (3.43 +/- 0.92 vs 2.82 +/- 0.60, P = 0.034, 4.32 +/- 0.51 vs 3.75 +/- 1.05, P = 0.039). The immunohistochemical scores of Cav1.3 expression were significantly higher than Cav1.2 in colon of both two group rats (P = 0.003, 0.005). Similarly, the expression of Cav1.2 and Cav1.3 mRNA increased in colon of D-IBS model rats as compared with those in normal control rats (1.18 +/- 0.15 vs 1.06 +/- 0.12, P = 0.023, 1.32 +/- 0.13 vs 1.23 +/- 0.13, P = 0.033). The expression of Cav1.3 mRNA was significantly higher than Cav1.2 in colon of both two group rats (P = 0.038, 0.012). The traditional modeling of irritable bowel syndrome in rats alters the expression of Cav1.2 and Cav1.3. It may be directly related to the generation of enhanced colonic contraction in D-IBS. In addition, Cav1.3 may play a more important role than Cav1.2 in colonic contractility. It offers another potential therapeutic target in the treatment of irritable bowel syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
